未经批准:在早期大流行期间,对COVID-19患者进行了恢复期血浆输注(CPI),具有混合的治疗效果。然而,CPI对ADAMTS13-VWF轴和血管内皮功能的影响尚不清楚.
未经评估:60例住院的COVID-19患者被纳入研究;46例接受CPI,14例接受无CPI。血浆ADAMTS13活性,VWF抗原,在治疗前和治疗后24小时评估内皮syndecan-1和可溶性血栓调节蛋白(sTM)。
未经证实:重症和重症COVID-19患者血浆ADAMTS13活性明显低于健康对照组。相反,这些患者显示VWF抗原显著升高.这导致这些患者中ADAMTS13与VWF的比率显著降低。每个患者的血浆ADAMTS13活性水平在整个住院期间保持相对恒定。CPI后24小时,在所有患者中,血浆ADAMTS13活性从基线增加了12%,在存活者中增加了21%。相比之下,血浆VWF抗原水平随时间显著变化.患者死亡后24小时血浆VWF抗原从基线显着降低,而那些幸存下来的人却没有。此外,重症和危重症COVID-19患者血浆syndecan-1和sTM水平显着升高,与免疫性血栓性血小板减少性紫癜患者相似。在CPI后24小时,syndecan-1和sTM水平均显著降低。
UNASSIGNED:我们的结果表明,重症和危重症COVID-19患者血浆ADAMTS13活性相对缺乏和内皮损伤,在CPI治疗后可以适度改善。
UNASSIGNED: Convalescent plasma infusion (CPI) was given to patients with COVID-19 during the early pandemic with mixed therapeutic efficacy. However, the impacts of CPI on the ADAMTS13-von Willebrand factor (VWF) axis and vascular endothelial functions are not known.
UNASSIGNED: To determine the impacts of CPI on the ADAMTS13-VWF axis and vascular endothelial functions.
UNASSIGNED: Sixty hospitalized patients with COVID-19 were enrolled in the study; 46 received CPI and 14 received no CPI. Plasma ADAMTS13 activity, VWF antigen, endothelial syndecan-1, and soluble thrombomodulin (sTM) were assessed before and 24 hours after treatment.
UNASSIGNED: Patients with severe and critical COVID-19 exhibited significantly lower plasma ADAMTS13 activity than the healthy controls. Conversely, these patients showed a significantly increased VWF antigen. This resulted in markedly reduced ratios of ADAMTS13 to VWF in these patients. The levels of plasma ADAMTS13 activity in each patient remained relatively constant throughout hospitalization. Twenty-four hours following CPI, plasma ADAMTS13 activity increased by ∼12% from the baseline in all patients and ∼21% in those who survived. In contrast, plasma levels of VWF antigen varied significantly over time. Patients who died exhibited a significant reduction of plasma VWF antigen from the baseline 24 hours following CPI, whereas those who survived did not. Furthermore, patients with severe and critical COVID-19 showed significantly elevated plasma levels of syndecan-1 and sTM, similar to those found in patients with immune thrombotic thrombocytopenic purpura. Both syndecan-1 and sTM levels were significantly reduced 24 hours following CPI.
UNASSIGNED: Our results demonstrate the relative deficiency of plasma ADAMTS13 activity and endothelial damage in patients with severe and critical COVID-19, which could be modestly improved following CPI therapy.